Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: GlobeNewswire
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients living with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC) now have improved access to an important therapy, as the permanent Healthcare Common Procedure Coding System Level II J Code for ZUSDURI™ (mitomycin) for intravesical solution became effective on January 1, 2026. The new code, J9282, assigned by the Centers for Medicare & Medicaid Services, is expected to streamline billing and reimbursement processes across hospital outpatient and physician office settings, reducing administrative delays that often stand between patients and timely treatment. “Bladder cancer patients repeatedly share with us that delays in access to treatment, not just the disease itself, can be one of the most stressful
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
URGN
Earnings
- 11/6/25 - Beat
URGN
Analyst Actions
- 10/27/25 - HC Wainwright
URGN
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- URGN's page on the SEC website